Mabwell passes Brazilian GMP inspection for denosumab
August 10, 2026 | 11:12
Mabwell, dual-listed under 688062.SH and 02493.HK, announced its subsidiary T-mab passed the Brazilian Health Regulatory Agency's GMP inspection for its denosumab injections, marking a second PIC/S GMP certification.
Mobile Version